Global Mass Spectrometry Market Report (2022 to 2027) – Players Include 908 Devices, AB SCIEX, Advion and Agena Biosciences –

Global Mass Spectrometry Market Report (2022 to 2027) – Players Include 908 Devices, AB SCIEX, Advion and Agena Biosciences –

Global Mass Spectrometry Market Report (2022 to 2027) – Players Include 908 Devices, AB SCIEX, Advion and Agena Biosciences –

DUBLIN–(BUSINESS WIRE)–The “Mass Spectrometry Market – Forecasts from 2022 to 2027” report has been added to’s offering.

Mass spectrometry is a process carried out to find the mass to charge (m/z) ratio of molecules present in a sample to be tested. The mass to charge ratio helps find useful information like the exact molecular weight of a molecule present, which can lead to identifying an unknown compound.

Mass spectrometry also helps understand different chemical properties and structural orientations of the molecules present in the testing sample. It adopts the ionization of the molecules by an ionization source, followed by acceleration so that the ions have equal kinetic energy.

Under the influence of both electric and magnetic fields, the ions deflect in accordance with the charge present on them, and finally, they are detected electrically via a detector present at the end of the spectrometric system. The real-life applications of the mass spectrometry market are vast in pharmaceutical, drug, biotechnology, and other similar sectors. With high R&D investments and developments in the pharmaceutical as well as the biotechnology industry, the growth in the mass spectrometry market is anticipated to increase substantially during the forecast period.

However, the advanced technological setup needed for successful mass spectroscopy research comes at expensive pricing. It may take significantly longer periods to develop, which is quite a challenge to overcome by this industry, hence negatively impacting the market share. Also, the lack of skill and technical knowledge needed to carry out precise and accurate mass spectrometry will be a preliminary factor restraining the mass spectrometry market size globally during the forecast period and beyond.

High R&D initiatives in the pharmaceutical and biotech segment

The pharmaceutical and biotech industry have witnessed significant funding and R&D investment and are anticipated to add to the numbers in both dimensions. As per the Biotechnology Innovation Report (BIO) 2020, the number of patents granted in the US in the biotechnology field rose about 17% from 2016 to 2019. Also, the same report (BIO) stated that the venture capital investments from the years 2016 to 2019 totalled to exceed USD 102 billion, with 2018 and 2019 crossing the USD 30 billion mark.

Additionally, as per the United States Congressional Budget Office report released in April 2021, the US biopharmaceutical industry invested USD 83 billion on R&D in the year 2019, which is nearly ten times the amount spent in the 1980s every year. In a 2020 data report published by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the EU-28 pharmaceutical industry invested EUR 37.5 billion in R&D.

The same report stated an investment of about EUR 14 billion in pharmaceutical R&D by Japan. With high R&D investments and capital funding, the pharma and biotech industry is in for rapid future growth; thus, their rise is anticipated to propel the market size of mass spectrometry in the forecast period.

Lack of talent, Expensive pricing, and long periods to develop

The manufacturing of mass spectrometers and related devices can be too complex in design, and they come at high prices to the end consumer, such as pharma and biotech companies. In a journal published in October 2019 by Wiley Analytical Science, a spectrometer required for space applications can take up to a decade to manufacture and even cost a couple of million dollars.

Such expensive pricing and complex design can seem unfeasible for several potential user companies of the mass spectrometry market to adopt on a high scale level. According to the 2021 Technology and Innovation Report of the United Nations Conference on Trade and Development (UNCTAD), in the highly technical field of gene- editing, there lies a shortage of scientific personnel with relevant experience globally, with a higher shortage in developing countries. Such factors are expected to restrain the mass spectrometry market globally during the forecast period.

US to see significant growth in the Mass Spectrometry Market

The United States of America is projected to grow substantially in the global mass spectrometry market share. As per the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) 2021 Facts and Figures Report, the spending on the pharma industry by the US will increase from USD 485 billion in 2018 to approximately USD 650 billion in 2023 at a CAGR of 4-7% which is higher than the projected global increase.

Companies Mentioned

  • 908 Devices
  • Advion
  • Agena Biosciences
  • Bioflyte
  • Biognosys
  • Chiesi
  • GlaxoSmithKline (GSK)
  • Intervenn Bioscience
  • Sphere Fluidics

Market Segmentation:

By Mass Analyzer/Ion Separation

  • Quadrupole Mass Analyzer
  • Time of flight Mass Analyzer
  • Magnetic Sector Mass Analyzer
  • Electrostatic Mass Analyzer
  • Quadrupole Ion Trap Mass Analyzer
  • Ion Cyclotron Resonance
  • Others

By Industry

  • Pharmaceutical
  • Biotechnology
  • Space Research
  • Food Testing
  • Others

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900